Taken together, our report grants candidacy to the E3 ubiquitin ligase activity of MKRN2 and the phosphatase activity of its substrate PPP2CA as novel ccRCC therapeutic targets. The gene discussed is PPP2CA; the disease is nonpapillary renal cell carcinoma.